| CN111184708A507
|
3CLpro |
Application of silver monoethyl
fumarate in resisting novel coronavirus infection |
small molecules |
| CN111184707A508
|
3CLpro |
Use of tolfenamic acid or
a pharmaceutically acceptable salt thereof in the preparation of medicament
for preventing and/or treating novel coronavirus inflammation |
small molecules |
| CN111150833A509
|
RdRp |
Application
of LTX-315 in
preparing products for inhibiting coronavirus |
small molecules |
| CN111135184A510
|
RdRp |
Application of GS-441524
in preparing novel coronavirus SARS-CoV-2 inhibitor |
small molecules |
| CN111135167A511
|
3CLpro |
Application
of GC376 in
preparing novel coronavirus SARS-CoV-2 inhibitor |
small molecules |
| CN111135166A512
|
RdRp,
3CLpro |
Pharmaceutical
composition
consisting of GC376 and GS-441524 and application thereof in inhibiting
novel coronavirus |
small molecules |
| CN111053909A513
|
3CLpro, IL-6 |
Application of
2019-nCoV
3CL hydrolase inhibitor and IL-6 monoclonal antibody in preparing
medicament for treating coronavirus disease 2019 |
small molecules |
| CN110960532A514
|
RdRp |
Composition containing benzylisoquinoline
alkaloid and trans-resveratrol for treating coronavirus
infection |
small molecules |
| CN111166768A515
|
ACE2 |
Overexpression
ACE2 mesenchyma
cell in the preparation of medicine for treating new coronavirus application
of drugs and preparation method thereof |
biologics |
| CN111172195A516
|
SARS-CoV-2, ORF1ab, nucleocapsid protein |
Preparation method of gene
therapy product for treating COVID-19 |
biologics |
| CN111153991A517
|
nucleocapsid protein |
A human SARS-CoV-2 monoclonal
antibody and preparation method and application thereof |
biologics |
| CN111139242A518
|
SARS-CoV-2 |
Small-interfering nucleic
acid, and its application for preparing pharmaceutical composition
for preventing and/or treating new coronavirus pneumonia |
biologics |
| CN111139241A519
|
SARS-CoV-2 |
Small interfering nucleic
acid for inhibiting new coronavirus and its composition and application |
biologics |
| KR2020032050520
|
SARS-CoV-2 |
COVID-19 virus customized
triple knockout DNA treatment |
biologics |
